The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...

Hims & Hers Health shares tumbled nearly 35% Monday after Novo Nordisk said it is pulling out of its partnership with the ...

诺和诺德公司周二宣布将停止与Hims & Hers的合作，终止通过NovoCare直接获取Wegovy的渠道。这家丹麦制药公司将拆股的主要原因归结为监管不合规和品牌保护问题，特别指出了Hims & Hers的营销做法以及继续销售复合Wegovy的个性化剂量。

Herb Greenberg, 'Herb on the Street' author, joins 'Power Lunch' to discuss Greenberg's thoughts on the terminated ...

Investing.com - 在制药巨头诺和诺德公司 (Novo Nordisk) (NYSE: NVO )宣布将终止与该远程医疗公司关于减肥药销售的合作后，Hims & Hers Health (NYSE: HIMS )股价暴跌20%。

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

It’s not often that investors come across the kind of companies that can yield a multi-bagger investment over the years.

First, the stock has sliced through two support levels. Shares broke through their 50-day moving average on Monday for the ...

Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell ...

The Novo Nordisk partnership ending does not alter my long-term bullish thesis on HIMS; the company is much more than just a ...

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.